2022
Drug Design Strategies: Role of Structural Modifications of Drug Candidates to Improve PK Parameters of New Drugs
NASSAR A. Drug Design Strategies: Role of Structural Modifications of Drug Candidates to Improve PK Parameters of New Drugs. 2022, 323-343. DOI: 10.1002/9781119851042.ch10.Peer-Reviewed Original ResearchDrug candidatesSuccessful drug designDrug metabolism scientistsDrug designDrug discoveryStructural modificationsMetabolic stabilityDiverse propertiesActive metabolitePass metabolismToxicity relationshipsSoft drugsReactive metabolitesInhibition/inductionMetabolism studiesPharmacokinetic issuesRenal clearanceSafe drugPK parametersMetabolic clearanceMetabolic inactivationNew drugsDrugsMetabolitesClearanceAccelerating Metabolite Identification Mass Spectrometry Technology Drives Metabolite Identification Studies Forward
NASSAR A. Accelerating Metabolite Identification Mass Spectrometry Technology Drives Metabolite Identification Studies Forward. 2022, 267-302. DOI: 10.1002/9781119851042.ch8.Peer-Reviewed Original ResearchDrug candidatesDrug discoveryLC-MSLiquid chromatography-mass spectrometryChromatography-mass spectrometryMetabolite identification studiesSuccessful drug candidatesFlight mass spectrometryDrug discovery effortsMass spectrometry technologyTriple quadrupoleADMET studiesStructural assignmentMass spectrometryMetabolite characterizationLead compoundsSpectrometry technologyIon trapDiscovery effortsOverall safety profileHuman-specific metabolitesSpectrometryDrug development processMetabolism issuesMetabolite profilingRole of Structural Modifications of Drug Candidates to Enhance Metabolic Stability
Nassar A. Role of Structural Modifications of Drug Candidates to Enhance Metabolic Stability. 2022, 303-322. DOI: 10.1002/9781119851042.ch9.Peer-Reviewed Original ResearchDrug candidatesStructural modificationsMetabolic stabilityDrug discovery processADME propertiesMetabolite characterizationDrug designDrug discoveryBalance of propertiesToxicity relationshipsExcretion studiesMetabolic instabilityDiscovery processHuman patientsStabilityPropertiesSuccess rateModificationDrugsCandidatesCharacterizationAbsorptionPatients
2016
UPLC–MS for metabolomics: a giant step forward in support of pharmaceutical research
Nassar AF, Wu T, Nassar SF, Wisnewski AV. UPLC–MS for metabolomics: a giant step forward in support of pharmaceutical research. Drug Discovery Today 2016, 22: 463-470. PMID: 27919805, PMCID: PMC5721520, DOI: 10.1016/j.drudis.2016.11.020.Peer-Reviewed Original Research
2010
Approaches to Performing Metabolite Elucidation: One Key to Success in Drug Discovery and Development
Nassar A. Approaches to Performing Metabolite Elucidation: One Key to Success in Drug Discovery and Development. 2010, 1-23. DOI: 10.1002/9780470571224.pse108.Peer-Reviewed Original ResearchMinimizing the Potential for Drug Bioactivation of Drug Candidates to Success in Clinical Development
Nassar A. Minimizing the Potential for Drug Bioactivation of Drug Candidates to Success in Clinical Development. 2010, 1-24. DOI: 10.1002/9780470571224.pse111.Peer-Reviewed Original ResearchDrug candidatesIdiosyncratic drug reactionsNew drug candidatesReactive metabolitesDrug discoveryDrug bioactivationDrug-metabolizing enzymesHuman drug-metabolizing enzymesPotential toxicitySafety profileDrug reactionsClinical developmentPreclinical phaseSubtle evidenceReactionRecent effortsToxicityMetabolitesCandidates
2008
Approaches to Performing Metabolite Elucidation: One Key to Success in Drug Discovery and Development
Nassar A. Approaches to Performing Metabolite Elucidation: One Key to Success in Drug Discovery and Development. 2008, 229-251. DOI: 10.1002/9780470439265.ch9.Peer-Reviewed Original Research